Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.